Abstract:Background: Sodium-glucose cotransporter 2 (SGLT2), also known as solute carrier family 5 member 2 (SLC5A2), is a promising target for a new class of drugs primarily established as kidney-targeting, effective glucose-lowering agents used in diabetes mellitus (DM) patients. Increasing evidence indicates that besides renal effects, SGLT2 inhibitors (SGLT2i) have also a systemic impact via indirectly targeting the heart and other tissues. Our hypothesis states that the pleiotropic effects of SGLT2i are associated with their binding force, location of targets in the SGLT2 networks, targets involvement in signaling pathways, and their tissue-specific expression. Methods: Thus, to investigate differences in SGLT2i impact on human organisms, we re-created the SGLT2 interaction network incorporating its inhibitors and metformin and analyzed its tissue-specific expression using publicly available datasets. We analyzed it in the context of the so-called key terms ( autophagy, oxidative stress, aging, senescence, inflammation, AMPK pathways, and mTOR pathways) which seem to be crucial to elucidating the SGLT2 role in a variety of clinical manifestations. Results: Analysis of SGLT2 and its network components' expression confidence identified selected organs in the following order: kidney, liver, adipose tissue, blood, heart, muscle, intestine, brain, and artery according to the TISSUES database. Drug repurposing analysis of known SGLT2i pointed out the influence of SGLT1 regulators on the heart and intestine tissue. Additionally, dapagliflozin seems to also have a stronger impact on brain tissue through the regulation of SGLT3 and SLC5A11. The shortest path analysis identified interaction SIRT1-SGLT2 among the top five interactions across six from seven analyzed networks associated with the key terms. Other top first-level SGLT2 interactors associated with key terms were not only ADIPOQ, INS, GLUT4, ACE, and GLUT1 but also less recognized ILK and ADCY7. Among other interactors which appeared in multiple shortest-path analyses were GPT, COG2, and MGAM. Enrichment analysis of SGLT2 network components showed the highest overrepresentation of hypertensive disease, DM-related diseases for both levels of SGLT2 interactors. Additionally, for the extended SGLT2 network, we observed enrichment in obesity (including SGLT1), cancer-related terms, neuroactive ligand-receptor interaction, and neutrophil-mediated immunity. Conclusion: This study provides comprehensive and ranked information about the SGLT2 interaction network in the context of tissue expression and can help to predict the clinical effects of the SGLT2i.

Structural basis of inhibition of the human SGLT2–MAP17 glucose transporter

Structural Mechanism of SGLT1 Inhibitors

Structures of Human SGLT in the Occluded State Reveal Conformational Changes During Sugar Transport

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

Structures Reveal How SGLT Inhibitors Work.

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening.

Crystal Structure of the Human Glucose Transporter GLUT1

Molecular basis for inhibiting human glucose transporters by exofacial inhibitors

Molecular Basis of Ligand Recognition and Transport by Glucose Transporters

Mechanistic Study of Human Glucose Transport Mediated by GLUT1

In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis

Structural insights into human organic cation transporter 1 transport and inhibition

Cryo-EM structure of human glucose transporter GLUT4

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

Molecular basis of inhibition of the amino acid transporter B AT1 (SLC6A19)

Synthesis, Crystal structure, Spectral analysis, DFT calculations, Docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative

Aglycone Exploration of C-arylglucoside Inhibitors of Renal Sodium-Dependent Glucose Transporter SGLT2.

Transmembrane IV of the high-affinity sodium-glucose cotransporter participates in sugar binding.